AstraZeneca Mexico – Ugo de Jacobis, President
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
AstraZeneca is one of only a handful of pure-play biopharmaceutical companies to span the entire value chain of a medicine from discovery, early- and late-stage development to manufacturing and distribution, and the global commercialisation of primary care, specialty care-led and specialty care medicines that transform lives. The company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). It is also active in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. In Mexico the company relies on manufacturing capabilities and a staff of 150 people.
Contact details
AstraZeneca S.A. de C.V.
Periférico Sur No. 4305, 5to piso
Col. Jardines de la Montaña, Del. Tlalpan
CP 14210 México DF
MEXICO
Tel: +52 (55) 5374 9600
Website: www.astrazeneca.com/mexico
AstraZeneca’s global strategic objectives are to achieve scientific leadership, to return to growth and to be a great place to work. The newly appointed president of the Mexico subsidiary discusses…
There have been a lot of changes in the Mexican pharmaceutical industry in the last four to five years, most notably the new drug registration process being put in place.…
Gent Hoxha, founder and CEO of lab equipment specialist Aspelab, explains the company’s growth strategy in Mexico, the intricacies of the Mexican medtech market, and how Aspelab’s solutions enhance both…
Victor Casasola, CEO at Canitec, explains the unique business model of his Mexican medical devices success story, offering an integral service to its clients, and showcases the high added value…
Fausto Hernández, CEO at ValidPro, explains the unique business model of the company as well as the high added value of its qualification and validation services; offering integral solution that…
Martin Ferrari del Sel, country manager at Dräger Mexico, explains the importance of enhancing the efficiency ratios in public and private hospitals, considering the shortage of health infrastructure to cover…
Armando Martínez, general manager at Beckman Coulter Mexico, explains the company’s unique business model Coulter, the strong added-value of its broad and innovative healthcare solutions, and how they help improve…
Abelardo Meneses García, General Director at the National Cancer Institute of Mexico (INCan), explains the evolution of cancer’s footprint in Mexico and showcases how the institute has been investing in…
José Luis Hernández, general manager at Kedrion Mexico, explains the strategy followed by the affiliate in Mexico to obtain success during the past eight years and showcases the added value…
Maarten Pouw, business unit director of Mexico and Latin America at DSM Sinochem Pharmaceuticals, explains the crucial role that sustainable antibiotics play in combating antimicrobial resistance and showcases the company’s…
GM Gerardo Torres-Septién explains how Grupo Rasch has managed to grow during the last two years and showcases the added value of its solutions to help the pharmaceutical industry enhance…
Juan Francisco Hernández, general manager of Latin America at Wockhardt, showcases the added value of the company to the entire region based on quality, safety and cost-effective medicines targeting diabetes,…
María Teresa Lopez, managing director at Zimmer Biomet Mexico, discusses the medtech company’s strong commitment to Mexico as well as the high added value of its broad and innovative health…
Alberto Wicker, CEO at Signufarma, explains how patient compliance programs can enhance the national healthcare system through reducing the cost of treatment as well as improving patients’ quality of life…
See our Cookie Privacy Policy Here
